GSK Entered into an Option Agreement with Mersana to Co-Development and Commercialize XMT-2056 for the Treatment of Cancer
Shots:
- Mersana to receive $100M up front. If GSK exercises its option, Mersana will eligible to receive ~$1.36B in option exercise, development, regulatory & commercial milestones
- Mersana also holds options for US profit-sharing & co-promotion of XMT-2056 in the US. If it exercises its option, Mersana will receive tiered royalty in Ex-US markets. If not, it will receive double-digit royalties on global net sales
- GSK gets an exclusive license option globally to co-develop and commercialize XMT-2056 which targets tumor-resident immune cells & tumor cells to stimulate the innate immune system through STING signaling. The P-I trial of XMT-2056 is expected to be initiated for HER2-expressing tumors
Ref: Mersana | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
